Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial

Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial

Abstract Background The prognosis for non‐small cell lung cancer (NSCLC) patients treated with standard platinum‐based chemotherapy was suboptimal, with safety concerns. Following encouraging results from a preliminary phase I study, this phase II trial investigated the efficacy and safety of first‐...

Full description

Saved in:
Bibliographic Details
Main Authors: Tianqing Chu, Hua Zhong, Zhuang Yu, Jing Wang, Yanqiu Zhao, Xiaoqian Mu, Xinmin Yu, Xun Shi, Qingming Shi, Maojing Guan, Cuimin Ding, Nan Geng, Jialin Qian, Baohui Han
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Cancer Communications
Subjects:
non‐small cell lung cancer
metastatic
phase II trial
sintilimab
anlotinib
treatment response
Online Access:https://doi.org/10.1002/cac2.12654
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cac2.12654

Similar Items